Clinical Data This analysis of CANVAS examined two high-CV-risk type 2 diabetes patient groups: those with a history of CV disease (secondary prevention) and those with only risk factors for CV disease (primary prevention). In this analysis, both patient groups showed CV outcomes consistent with the overall reduction seen in CV events: primary (HR: 0.98; 95% CI: 0.74 to 1.30) and secondary (HR: 0.82; 95% CI: 0.72 to 0.95), with no statistical evidence of between-group heterogeneity (p = 0.18). Comparable effects were also observed for other CV and renal outcomes across the primary and secondary prevention groups. Page 2 of 7 As previously reported, in the total cohort of the CANVAS Program, canagliflozin reduced the combined risk of CV death, nonfatal myocardial infarction (MI) and nonfatal stroke by 14 percent, compared to placebo (HR: 0.86; 95% CI: 0.75 to 0.97, p=0.0158).